MoonLake Immunotherapeutics (MLTX) Competitors $53.12 -1.18 (-2.16%) As of 02:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLTX vs. ASND, VTRS, RDY, QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, and RVMDShould you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. MoonLake Immunotherapeutics vs. Its Competitors Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Ascendis Pharma A/S (NASDAQ:ASND) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership. Do analysts recommend ASND or MLTX? Ascendis Pharma A/S presently has a consensus price target of $244.36, suggesting a potential upside of 24.41%. MoonLake Immunotherapeutics has a consensus price target of $74.43, suggesting a potential upside of 40.10%. Given MoonLake Immunotherapeutics' higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00MoonLake Immunotherapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Is ASND or MLTX more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -54.94%. Ascendis Pharma A/S's return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-54.94% N/A -24.31% MoonLake Immunotherapeutics N/A -40.98%-35.81% Does the media favor ASND or MLTX? In the previous week, Ascendis Pharma A/S had 3 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 11 mentions for MoonLake Immunotherapeutics. Ascendis Pharma A/S's average media sentiment score of 1.30 beat MoonLake Immunotherapeutics' score of 1.28 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, ASND or MLTX? MoonLake Immunotherapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$490.75M24.50-$409.12M-$5.16-38.06MoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.78-19.11 Do institutionals & insiders hold more shares of ASND or MLTX? 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, ASND or MLTX? Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. SummaryAscendis Pharma A/S beats MoonLake Immunotherapeutics on 8 of the 15 factors compared between the two stocks. Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLTX vs. The Competition Export to ExcelMetricMoonLake ImmunotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.40B$3.15B$5.81B$10.17BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-19.0321.3774.6226.02Price / SalesN/A294.32466.0690.52Price / CashN/A45.3337.0859.91Price / Book7.499.6212.166.30Net Income-$118.94M-$53.29M$3.29B$270.86M7 Day Performance-10.62%0.35%1.07%3.41%1 Month Performance-3.13%8.99%7.38%6.56%1 Year Performance4.09%12.97%63.13%28.27% MoonLake Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLTXMoonLake Immunotherapeutics2.507 of 5 stars$53.13-2.2%$74.43+40.1%+17.0%$3.40BN/A-19.032ASNDAscendis Pharma A/S3.1082 of 5 stars$205.22-0.3%$244.36+19.1%+75.0%$12.60B$393.54M-39.771,017Positive NewsVTRSViatris1.6727 of 5 stars$10.48-0.2%$10.40-0.8%-10.3%$12.24B$14.74B-3.6132,000RDYDr. Reddy's Laboratories2.484 of 5 stars$14.27-0.5%$16.95+18.8%-7.1%$11.97B$3.81B21.6127,811Positive NewsQGENQIAGEN4.468 of 5 stars$47.62+0.1%$49.69+4.4%+3.3%$10.57B$1.98B28.135,765Positive NewsBBIOBridgeBio Pharma4.4486 of 5 stars$54.29+1.7%$63.35+16.7%+87.9%$10.20B$221.90M-13.27400Positive NewsAnalyst ForecastMRNAModerna4.5036 of 5 stars$24.83-1.2%$42.88+72.7%-68.1%$9.78B$3.24B-3.305,800Positive NewsVRNAVerona Pharma PLC American Depositary Share2.1761 of 5 stars$106.300.0%$109.00+2.5%+252.9%$9.20B$42.28M-107.3730Positive NewsELANElanco Animal Health2.6335 of 5 stars$19.02+3.2%$17.33-8.9%+29.8%$9.16B$4.44B22.129,000Positive NewsROIVRoivant Sciences2.9462 of 5 stars$12.91-0.1%$16.38+26.8%+16.4%$8.82B$29.05M-18.44860News CoveragePositive NewsOptions VolumeRVMDRevolution Medicines4.2417 of 5 stars$41.06+1.4%$72.00+75.4%+11.0%$7.57B$11.58M-9.12250Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies ASND Competitors VTRS Competitors RDY Competitors QGEN Competitors BBIO Competitors MRNA Competitors VRNA Competitors ELAN Competitors ROIV Competitors RVMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLTX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredElon’s new AI play could hand regular Americans a Tesla‑like paydayElon Musk just launched his boldest AI project yet... And if history is any guide — it could make early inv...Behind the Markets | SponsoredOne tiny company just cracked Google’s $19B problemCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MLTX Stock Alerts